1352. A Randomized Multicenter Study of Daptomycin Versus Standard of Care in Pediatric Subjects with Bacteremia Caused by Staphylococcus aureus
Session: Poster Abstract Session: Clinical Trials
Friday, October 28, 2016
Room: Poster Hall
Posters
  • 2016_IDW_1352_Arietta_Randomized_Multicenter_Poster.pdf (374.9 kB)
  • Background: Infections due to Staphylococcus aureus in children are a growing health concern. Data evaluating daptomycin (DAP) versus standard of care (SOC) in pediatric patients aged 1–17 years with S. aureus bacteremia are presented.

    Methods: In a randomized, multicenter, open-label study, patients were assigned 2:1 to intravenous DAP or SOC (vancomycin, semi-synthetic penicillin, 1st-generation cephalosporin, or clindamycin). DAP dose varied by age with the goal of achieving exposures similar to adults: ages 1–6 years, 12 mg/kg once daily (QD); 7–11 years, 9 mg/kg QD; 12–17 years, 7 mg/kg QD. The primary endpoint was safety (incidence of adverse events [AEs]). Secondary endpoints were favorable clinical response (cure/improvement) at the test of cure (TOC) visit and overall therapeutic success (combined favorable clinical and microbiological response) at TOC, based on blinded evaluator assessments. The study was not powered to detect statistical differences between arms.

    Results: Overall, 81 patients with bacteremia (73 [90.1%] with S. aureus; 8 [9.9%] with coagulase-negative Staphylococcus [CoNS]/other) were randomized and treated (Table). Rates of treatment-related AEs (TRAEs) were similar between arms. There were no severe or serious TRAEs including deaths. At TOC, 45/51 (88.2%) evaluable DAP and 17/22 (77.3%) SOC patients had favorable clinical response, and 37/51 (72.5%) DAP and 13/22 (59.1%) SOC patients had overall success.

    Conclusion: DAP was generally safe and well tolerated and was as effective as SOC in the treatment of S. aureus bacteremia in pediatric patients.

    Antonio Arrieta, MD, FIDSA1, John S. Bradley, MD, FIDSA, FPIDS2, Myra W. Popejoy, PharmD3, Mekki Bensaci, PhD, MSc3, Anjana Grandhi, PhD3 and Nicholas Kartsonis, MD3, (1)Infectious Diseases, Children's Hospital of Orange County, Orange, CA, (2)Pediatric Infectious Diseases, Rady Children’s Hospital, University of California at San Diego School of Medicine, San Diego, CA, (3)Merck & Co., Inc., Kenilworth, NJ

    Disclosures:

    A. Arrieta, None

    J. S. Bradley, None

    M. W. Popejoy, Merck: Employee , Salary

    M. Bensaci, Merck: Employee , Salary

    A. Grandhi, Merck: Employee , Salary

    N. Kartsonis, Merck: Employee , Salary

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.